Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471234 | 0.99 | HPGD (0.61) | HPGDTSHRRECQLNAAAEPHX1 | |
| SCHEMBL23471170 | 0.99 | HPGD (0.61) | HPGDTSHRRECQLNAAAEPHX1 | |
| SCHEMBL18665382 | 0.95 | TSHR (0.57) | HPGDTSHRRECQLALDH1A1HTT | |
| SCHEMBL10272750 | 0.89 | ALDH1A1 (0.51) | HPGDTSHRRECQLALDH1A1 | |
| SCHEMBL26499903 | 0.88 | GAA (0.52) | HPGDTSHRRECQLEPHX2 | |
| SCHEMBL17117364 | 0.87 | TRPV1 (0.63) | HPGDTSHRALDH1A1HTT | |
| SCHEMBL23471429 | 0.85 | TRPV1 (0.47) | HPGDTSHRALDH1A1HTT | |
| SCHEMBL23471187 | 0.85 | TRPV1 (0.47) | HPGDTSHRALDH1A1HTT | |
| SCHEMBL23471165 | 0.85 | TRPV1 (0.47) | HPGDTSHR | |
| SCHEMBL8125763 | 0.85 | L3MBTL1 (0.49) | HPGDTSHRRECQLHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4186888-A1 | COMPOUND AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | ModernaTX, Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2023-04-27 | — | — | US | disclosed |
| EP-3350157-B1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2022-01-05 | — | — | EP | disclosed |
| EP-3831841-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T Global Inc. (US) | 2021-06-09 | — | — | EP | disclosed |
| WO-2021076805-A1 | MRNAS ENCODING IMMUNE MODULATING POLYPEPTIDES AND USES THEREOF | Moderna TX, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021026358-A1 | COMPOSITIONS AND METHODS FOR ENHANCED DELIVERY OF AGENTS | Moderna TX, Inc. (US) | 2021-02-11 | — | — | WO | disclosed |
| WO-2021022173-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA INTERFERENCE AGENTS TO IMMUNE CELLS | MODERNATX, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2020061367-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
| WO-2019152557-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF AGENTS TO IMMUNE CELLS | MODERNATX, INC. (US) | 2019-08-08 | — | — | WO | disclosed |
| WO-2017200984-A1 | NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF | S&T GLOBAL INC. (US) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230130155-A1 | MRNAS ENCODING METABOLIC REPROGRAMMING POLYPEPTIDES AND USES THEREOF | HMOX1, CD209, HMOX2 | HPGD 539/4885TSHR 1695/4885RECQL 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.